HC Wainwright & Co. Assumes Monopar Therapeutics at Buy, Announces Price Target of $70
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Andres Y. Maldonado assumes Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $70.
HC Wainwright & Co. analyst Andres Y. Maldonado assumes Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $70.